{"id":"maintenance-chemotherapy-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infection risk"},{"rate":null,"effect":"Mucositis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Maintenance chemotherapy involves administering lower doses or intermittent cycles of chemotherapeutic agents following completion of primary induction therapy. This approach aims to eliminate residual disease, delay recurrence, and prolong progression-free and overall survival. The specific mechanism depends on the chemotherapy agents used, which typically target rapidly dividing cancer cells through DNA damage or mitotic inhibition.","oneSentence":"Maintenance chemotherapy 1 refers to a continuation of cytotoxic chemotherapy after initial induction treatment to sustain disease control and improve long-term outcomes.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:20:03.140Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer maintenance therapy (specific indication dependent on primary malignancy and induction regimen)"}]},"trialDetails":[{"nctId":"NCT02306161","phase":"PHASE3","title":"Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-12","conditions":"Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow","enrollment":312},{"nctId":"NCT06225596","phase":"PHASE2, PHASE3","title":"Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)","status":"RECRUITING","sponsor":"BicycleTx Limited","startDate":"2024-01-24","conditions":"Metastatic Urothelial Cancer","enrollment":956},{"nctId":"NCT07020065","phase":"PHASE2","title":"Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%","status":"NOT_YET_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2026-05","conditions":"Metastatic NSCLC - Non-Small Cell Lung Cancer","enrollment":156},{"nctId":"NCT04164082","phase":"PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-03-18","conditions":"Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8","enrollment":161},{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":80},{"nctId":"NCT05691478","phase":"PHASE2, PHASE3","title":"A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-03","conditions":"High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma","enrollment":1122},{"nctId":"NCT06824467","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-09","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":770},{"nctId":"NCT04301076","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATLL)","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-31","conditions":"Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma","enrollment":30},{"nctId":"NCT07491302","phase":"PHASE2","title":"Thumb Base Osteoarthritis: Ultrasound-guided Platelet-rich Plasma Versus Placebo Injection","status":"NOT_YET_RECRUITING","sponsor":"Goed Medisch Centrum","startDate":"2026-03","conditions":"Thumb Osteoarthritis","enrollment":88},{"nctId":"NCT05058651","phase":"PHASE2, PHASE3","title":"Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-28","conditions":"Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma","enrollment":189},{"nctId":"NCT07198074","phase":"PHASE3","title":"Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-01-27","conditions":"Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma","enrollment":255},{"nctId":"NCT03321643","phase":"PHASE1","title":"Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-18","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":24},{"nctId":"NCT07036380","phase":"PHASE2","title":"MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2025-12-22","conditions":"Advanced Biliary Tract Carcinoma","enrollment":75},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT07012044","phase":"PHASE1","title":"A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-30","conditions":"Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":47},{"nctId":"NCT04307576","phase":"PHASE3","title":"A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"Mats Heyman","startDate":"2020-07-13","conditions":"Leukemia, Acute Lymphoblastic","enrollment":6430},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT01861314","phase":"PHASE1","title":"Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-07-03","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Adult Acute Myeloid Leukemia","enrollment":15},{"nctId":"NCT07466238","phase":"NA","title":"HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2026-03-15","conditions":"Biliary Tract Cancer (BTC)","enrollment":40},{"nctId":"NCT03914612","phase":"PHASE3","title":"Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-22","conditions":"Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma","enrollment":813},{"nctId":"NCT03581292","phase":"PHASE2","title":"Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-11-06","conditions":"Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma","enrollment":38},{"nctId":"NCT05256225","phase":"PHASE3","title":"Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-16","conditions":"Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma","enrollment":360},{"nctId":"NCT07061977","phase":"PHASE3","title":"Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-11-05","conditions":"Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma","enrollment":336},{"nctId":"NCT06627647","phase":"PHASE3","title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-11-27","conditions":"Non-squamous Non-small Cell Lung Cancer","enrollment":878},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":"Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma","enrollment":16},{"nctId":"NCT05092958","phase":"PHASE3","title":"Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-03","conditions":"Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma","enrollment":654},{"nctId":"NCT07318558","phase":"PHASE3","title":"A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-02-16","conditions":"Ovarian Neoplasms, Ovarian Cancer","enrollment":900},{"nctId":"NCT05001880","phase":"PHASE2","title":"Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-22","conditions":"Peritoneal Malignant Mesothelioma","enrollment":66},{"nctId":"NCT05063552","phase":"PHASE2, PHASE3","title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-13","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":430},{"nctId":"NCT06096844","phase":"PHASE3","title":"Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-19","conditions":"Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8","enrollment":304},{"nctId":"NCT07407140","phase":"PHASE3","title":"VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-30","conditions":"AML, Adult","enrollment":300},{"nctId":"NCT02615184","phase":"PHASE2","title":"A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2023-05-23","conditions":"Erosive Esophagitis","enrollment":76},{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":"Ph+ ALL","enrollment":100},{"nctId":"NCT07493382","phase":"NA","title":"Retlirafusp Alfa Injection Combined Chemotherapy for Perioperative Treatment of Esophagogastric Junction Adenocarcinoma: A Single-Arm, Phase II Study of Safety and Efficacy","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-04-01","conditions":"GEJ Adenocarcinoma","enrollment":30},{"nctId":"NCT04107727","phase":"PHASE2","title":"Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2019-09-05","conditions":"Acute Myeloid Leukemia","enrollment":273},{"nctId":"NCT07221474","phase":"PHASE2","title":"A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-12","conditions":"Squamous Non-small Cell Lung Cancer","enrollment":180},{"nctId":"NCT07490288","phase":"NA","title":"Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"AML","enrollment":30},{"nctId":"NCT06580314","phase":"PHASE3","title":"Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2025-03-12","conditions":"Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014","enrollment":880},{"nctId":"NCT07300514","phase":"PHASE3","title":"Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-30","conditions":"Maintenance Treatment of Peripheral T-cell Lymphoma","enrollment":136},{"nctId":"NCT07392541","phase":"PHASE1, PHASE2","title":"Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2026-01-30","conditions":"Advanced Biliary Tract Carcinoma","enrollment":29},{"nctId":"NCT06897579","phase":"PHASE2","title":"Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-07","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":134},{"nctId":"NCT00338377","phase":"PHASE2","title":"Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-02-01","conditions":"Melanoma","enrollment":1230},{"nctId":"NCT07227597","phase":"PHASE1, PHASE2","title":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-29","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":170},{"nctId":"NCT07486726","phase":"PHASE1, PHASE2","title":"Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2026-03-15","conditions":"Acute Myeloid Leukemia (AML), Relapse Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia (AML)","enrollment":112},{"nctId":"NCT03635073","phase":"PHASE2","title":"A Study of Soticlestat in Adults and Children With Rare Epilepsies","status":"TERMINATED","sponsor":"Takeda","startDate":"2018-07-19","conditions":"Epilepsy, Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS)","enrollment":156},{"nctId":"NCT04430699","phase":"PHASE2","title":"Cisplatin+Pembrolizumab+RT in Vulvar Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-07-29","conditions":"Vulvar Cancer, Vulvar Squamous Cell Carcinoma","enrollment":24},{"nctId":"NCT04538664","phase":"PHASE3","title":"A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-10-13","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":308},{"nctId":"NCT03793361","phase":"PHASE2","title":"Phase II Study of Regorafenib as Maintenance Therapy","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2019-05-15","conditions":"Metastatic Soft Tissue Sarcoma","enrollment":127},{"nctId":"NCT06726265","phase":"PHASE3","title":"Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immutep S.A.S.","startDate":"2025-03-21","conditions":"Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","enrollment":756},{"nctId":"NCT07480356","phase":"PHASE3","title":"Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Protara Therapeutics","startDate":"2026-05","conditions":"Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ","enrollment":284},{"nctId":"NCT06211764","phase":"PHASE3","title":"A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-04-09","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":272},{"nctId":"NCT04077463","phase":"PHASE1","title":"A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-09-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":701},{"nctId":"NCT07476729","phase":"PHASE3","title":"International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)","status":"NOT_YET_RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2026-04-01","conditions":"B-Cell Acute Lymphoblastic Leukaemia","enrollment":750},{"nctId":"NCT02114229","phase":"PHASE2","title":"Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-14","conditions":"Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor","enrollment":125},{"nctId":"NCT02173756","phase":"PHASE3","title":"Evaluation of Oral Morphine Gel in Oral Mucositis Induced by Chemotherapy in Children and Young Adults","status":"TERMINATED","sponsor":"University Hospital, Strasbourg, France","startDate":"2014-06","conditions":"Cancer","enrollment":25},{"nctId":"NCT07472153","phase":"PHASE2, PHASE3","title":"PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer","status":"RECRUITING","sponsor":"N.N. Alexandrov National Cancer Centre","startDate":"2025-07-01","conditions":"Metastatic Cervical Cancer, Persistent Cervical Cancer, Recurrent Cervical Cancer","enrollment":120},{"nctId":"NCT07194044","phase":"PHASE1","title":"Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-02","conditions":"Metastatic Ewing Sarcoma","enrollment":15},{"nctId":"NCT04165070","phase":"PHASE1, PHASE2","title":"KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-12-19","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":450},{"nctId":"NCT06319820","phase":"PHASE3","title":"A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-04-18","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":641},{"nctId":"NCT07470450","phase":"NA","title":"Acute and Chronic Effects of Combined Training on BP in Hypertensives","status":"COMPLETED","sponsor":"Federal University of Rio Grande do Sul","startDate":"2025-07-26","conditions":"Dynamic Strength Exercise Session, Isometric Strength Exercise Session, Combined Exercise Session","enrollment":60},{"nctId":"NCT05022849","phase":"PHASE1","title":"A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-09-28","conditions":"Prostatic Neoplasms","enrollment":15},{"nctId":"NCT06038539","phase":"PHASE3","title":"Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer","status":"TERMINATED","sponsor":"Biocon Biologics UK Ltd","startDate":"2025-01-06","conditions":"HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients","enrollment":55},{"nctId":"NCT07469241","phase":"PHASE2","title":"Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-10","conditions":"Advanced Esophageal Squamous Cell Carcinoma, Unresectable Esophageal Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT06919965","phase":"PHASE3","title":"A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-09-10","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":220},{"nctId":"NCT03164616","phase":"PHASE3","title":"Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-06-01","conditions":"Non Small Cell Lung Cancer NSCLC","enrollment":1186},{"nctId":"NCT06142396","phase":"EARLY_PHASE1","title":"Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure","status":"RECRUITING","sponsor":"Augusta University","startDate":"2024-11-01","conditions":"Multiple Myeloma, Renal Failure","enrollment":30},{"nctId":"NCT06333899","phase":"EARLY_PHASE1","title":"Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2025-08-03","conditions":"High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma","enrollment":15},{"nctId":"NCT07466316","phase":"PHASE3","title":"A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-22","conditions":"Rhabdomyosarcoma","enrollment":342},{"nctId":"NCT06091254","phase":"PHASE3","title":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-12","conditions":"Follicular Lymphoma (FL)","enrollment":822},{"nctId":"NCT06011772","phase":"EARLY_PHASE1","title":"EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2023-12-18","conditions":"Colo-rectal Cancer","enrollment":2},{"nctId":"NCT06775743","phase":"PHASE2","title":"ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-01-15","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Mutation Positive Advanced Non Small Cell Lung Cancer","enrollment":53},{"nctId":"NCT02213913","phase":"PHASE1, PHASE2","title":"Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2014-07-29","conditions":"Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell Lymphoma","enrollment":55},{"nctId":"NCT05378334","phase":"NA","title":"Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients","status":"RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2022-06-15","conditions":"Non-small Cell Lung Cancer","enrollment":82},{"nctId":"NCT03404193","phase":"PHASE2","title":"Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-01-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":235},{"nctId":"NCT06951646","phase":"PHASE2","title":"ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)","status":"RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2026-03-10","conditions":"Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)","enrollment":70},{"nctId":"NCT07455019","phase":"PHASE2","title":"A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-05-01","conditions":"Esophageal Cancer","enrollment":28},{"nctId":"NCT05306301","phase":"PHASE2","title":"Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2022-10-05","conditions":"Chemotherapy, Leukemia, Acute Lymphoblastic","enrollment":32},{"nctId":"NCT07454226","phase":"NA","title":"ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Ph-Like, Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT04222972","phase":"PHASE3","title":"A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2020-07-24","conditions":"RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung","enrollment":223},{"nctId":"NCT06253637","phase":"PHASE2","title":"Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2024-10-17","conditions":"T-Lymphocytic Leukemia, Acute","enrollment":31},{"nctId":"NCT05032820","phase":"PHASE2","title":"Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2022-01-05","conditions":"Multiple Myeloma","enrollment":40},{"nctId":"NCT05025059","phase":"NA","title":"Exercise During Chemotherapy in Older Women With Stage I-III Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-03","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8","enrollment":30},{"nctId":"NCT03601078","phase":"PHASE2","title":"An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2018-12-13","conditions":"Multiple Myeloma","enrollment":312},{"nctId":"NCT06951503","phase":"PHASE3","title":"AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-05-27","conditions":"Colorectal Adenocarcinoma","enrollment":560},{"nctId":"NCT05184712","phase":"PHASE3","title":"Phase 3 Clinical Study of AK112 for NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-01-25","conditions":"Non-Squamous Non-small Cell Lung Cancer","enrollment":322},{"nctId":"NCT05894239","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-09-08","conditions":"Metastatic Breast Cancer","enrollment":230},{"nctId":"NCT04542824","phase":"PHASE1, PHASE2","title":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-08-20","conditions":"Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma","enrollment":78},{"nctId":"NCT07446335","phase":"PHASE3","title":"A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2026-04","conditions":"Advanced Esophageal Squamous Cell Carcinoma","enrollment":578},{"nctId":"NCT06417814","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-10-04","conditions":"Metastatic Non-small Cell Lung Cancer","enrollment":744},{"nctId":"NCT07132684","phase":"PHASE3","title":"Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-08-31","conditions":"AML, Adult","enrollment":240},{"nctId":"NCT06457503","phase":"PHASE4","title":"A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer","status":"RECRUITING","sponsor":"Coherus Oncology, Inc.","startDate":"2024-11-01","conditions":"Nasopharyngeal Cancer Recurrent","enrollment":100},{"nctId":"NCT03150693","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia","status":"SUSPENDED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2017-09-20","conditions":"B Acute Lymphoblastic Leukemia","enrollment":310},{"nctId":"NCT02425904","phase":"PHASE2","title":"Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-05","conditions":"Langerhans Cell Histiocytosis","enrollment":25},{"nctId":"NCT07033819","phase":"PHASE2","title":"Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-06-25","conditions":"Ovarian Cancer","enrollment":48},{"nctId":"NCT07422519","phase":"NA","title":"Virtual Reality-Based Mindfulness as an Adjunct to Treatment as Usual in Treatment-Resistant Depression","status":"RECRUITING","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2025-09-18","conditions":"Depression - Major Depressive Disorder, Depression Disorder, Depression Chronic","enrollment":30},{"nctId":"NCT06578247","phase":"PHASE3","title":"Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-11-19","conditions":"Leukemia","enrollment":700},{"nctId":"NCT04602533","phase":"PHASE2","title":"Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Michael Hopp","startDate":"2020-12-21","conditions":"Small Cell Lung Cancer Limited Stage","enrollment":105},{"nctId":"NCT07440784","phase":"NA","title":"Impact Of Intermittent And Water-Only Fasting On Gene Expression And Tumor Markers In Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Khyber Medical University Peshawar","startDate":"2022-08-01","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT06532006","phase":"PHASE3","title":"A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2024-11-22","conditions":"Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer","enrollment":550},{"nctId":"NCT05739981","phase":"PHASE1, PHASE2","title":"Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer","status":"RECRUITING","sponsor":"Imunon","startDate":"2023-02-10","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Maintenance chemotherapy 1","genericName":"Maintenance chemotherapy 1","companyName":"Shanghai Proton and Heavy Ion Center","companyId":"shanghai-proton-and-heavy-ion-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Maintenance chemotherapy 1 refers to a continuation of cytotoxic chemotherapy after initial induction treatment to sustain disease control and improve long-term outcomes. Used for Cancer maintenance therapy (specific indication dependent on primary malignancy and induction regimen).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}